Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

The Quick Take
Markers released top-line results today after previously reporting the trial succeeded.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to Ars Technica.



